Bastide Group: Revenue of €526.7m in 2025-2026, Above Target
Bastide Group published on September 3, 2026 its revenue for the 2025-2026 financial year, ended June 30. Including the contribution of Experf, sold on June 1, 2026, total revenue reached €526.7m, above the target of at least €510m set at the beginning of the financial year. On the sole scope of continuing operations, as published in accordance with IFRS 5 standard, revenue came to €482.9m, growing by +7.6%, including +7.8% on an organic basis.
Annual Revenue of €482.9m on Continuing Operations, €526.7m Including Experf
On the scope of continuing operations, 2025-2026 revenue stood at €482.9m, compared to €448.8m for the previous year restated on the same basis, representing growth of +7.6% (+7.8% on an organic basis). Including Experf's contribution (€43.8m), total revenue reached €526.7m, beyond the guidance of at least €510m communicated at the beginning of the financial year, prior to the subsidiary's sale. The fourth quarter posted revenue of €122.2m, growing +6.4% in reported figures (+6.5% on an organic basis). This period includes the 4% tariff reduction on sleep apnea services, which came into effect on April 1, 2026 in France.
Home Healthcare Services and Community Care Drive Growth
Home healthcare services activities (Respiratory, Nutrition-Infusion-Diabetes-Stoma Care) represent 58.5% of revenue and grew +7.4% in the quarter (+7.5% on an organic basis), despite the tariff reduction on sleep apnea services. For the full year, Respiratory activity reached €177.1m, up +11.1% on an organic basis (+10.5% in reported figures due to the decline of the Canadian dollar and British pound). In France, organic growth stood at +9.6% despite successive tariff reductions (-5% on April 1, 2025 and -4% on April 1, 2026), and international operations grew +16.2% on an organic basis, driven by Intus in the United Kingdom and Medpro in Canada. Home Care came to €201.7m, up +5.2%, with the community care segment at €94.3m (+10.5%) and the stores/internet segment at €107.4m (+0.9%), the latter limited by VPH reform. Nutrition-Infusion-Diabetes-Stoma Care activity reached €104.2m (+7.7%), supported by Diabetes activity growth exceeding 20%.
Operating Margin Around 9% Confirmed and Leverage Expected Below 2.5x
The Group confirms its target operating margin around 9.0% in reported figures for the 2025-2026 financial year. For the 2026-2027 financial year, at constant scope, the Group indicates that it will once again exceed the €500m revenue threshold, with the precise target to be communicated upon publication of annual results at the end of October. The sale of Experf, announced in May 2026, should help reduce financial expenses and improve financial leverage, expected at a level slightly below 2.5x post-transaction (post-IFRS 16), compared to 3.6x as of June 30, 2024. The 2025-2026 annual results will be published on October 21, 2026 after trading hours.
